No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial
Year: 2017
Type: article
Source: Diabetes Care
DOI: 10.2337/dc17-1956
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Novo Nordisk
OpenAlex ID: W2778933123
